CN105732618A - Method for synthesizing 4-(2-oxo-piperidine-1-yl)aryl-carboxylic ethyl ester compound - Google Patents
Method for synthesizing 4-(2-oxo-piperidine-1-yl)aryl-carboxylic ethyl ester compound Download PDFInfo
- Publication number
- CN105732618A CN105732618A CN201610073279.5A CN201610073279A CN105732618A CN 105732618 A CN105732618 A CN 105732618A CN 201610073279 A CN201610073279 A CN 201610073279A CN 105732618 A CN105732618 A CN 105732618A
- Authority
- CN
- China
- Prior art keywords
- ethyl ester
- oxo
- ester compound
- reaction
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种合成4(2氧代哌啶1基)芳基羧酸乙酯类化合物的新方法,该方法以4(5氯戊酰胺基)芳基羧酸乙酯类化合物为反应原料,四氢呋喃和二氯甲烷作混合溶剂,在强碱氢化钠作用下发生内酰胺化反应得到产物4(2氧代哌啶1基)芳基羧酸乙酯类化合物。这类4(2氧代哌啶1基)芳基羧酸乙酯化合物含有合成用于预防血栓的口服抗凝剂的母体结构,具有很好的市场前景。采用本方法制备的4(2氧代哌啶1基)芳基羧酸乙酯类化合物具有产率高、纯度高,物料比较经济,应用价值广等优点,是一种较好的合成方法。The invention discloses a new method for synthesizing 4(2-oxopiperidinyl)aryl carboxylate ethyl esters. The raw materials, tetrahydrofuran and dichloromethane are used as a mixed solvent, and a lactamization reaction occurs under the action of a strong alkali sodium hydride to obtain the product 4 (2-oxopiperidinyl) aryl carboxylate ethyl esters. This type of ethyl 4(2-oxopiperidinyl)arylcarboxylate compound contains the parent structure for synthesizing oral anticoagulants for preventing thrombosis, and has a good market prospect. The ethyl 4(2-oxopiperidinyl)arylcarboxylate compound prepared by the method has the advantages of high yield, high purity, relatively economical materials, wide application value, etc., and is a better synthetic method.
Description
技术领域technical field
本发明涉及有机合成中的内酰胺化反应技术领域,具体涉及一种4-(2-氧代哌啶-1-基)芳基羧酸乙酯类化合物的合成新方法。The invention relates to the technical field of lactamization reaction in organic synthesis, in particular to a new method for synthesizing ethyl 4-(2-oxopiperidin-1-yl) aryl carboxylates.
背景技术Background technique
本发明所合成的4-(2-氧代哌啶-1-基)芳基羧酸乙酯类化合物可作为合成一种口服的选择性活化X因子抑制剂的中间体。该药物用于预防血栓,是第三个上市的新一代口服抗凝剂,其拥有“同类最佳”的临床试验结果,且降低大出血风险的效果十分显著,安全性和有效性均超出同类药物。介于此,该4-(2-氧代哌啶-1-基)芳基羧酸乙酯类化合物具有广阔的市场前景和很大的应用价值。之前也有很多方法合成该类化合物,例如文献WO2007001385A中提到的反应体系为三氟乙酸/原甲酸三乙酯,NMP,NaOEt在EtOH中,该反应用到的试剂种类较多,体系较为复杂,特别是用到除水体系三氟乙酸/原甲酸三乙酯。The 4-(2-oxopiperidin-1-yl) aryl carboxylate ethyl ester compound synthesized by the invention can be used as an intermediate for synthesizing an oral selective activation factor X inhibitor. The drug is used to prevent blood clots, and is the third new generation of oral anticoagulant on the market. It has the "best in class" clinical trial results, and the effect of reducing the risk of major bleeding is very significant, and its safety and efficacy are superior to similar drugs . Therefore, the ethyl 4-(2-oxopiperidin-1-yl)aryl carboxylate compound has broad market prospects and great application value. There are also many ways to synthesize such compounds before. For example, the reaction system mentioned in the document WO2007001385A is trifluoroacetic acid/triethyl orthoformate, NMP, and NaOEt in EtOH. There are many kinds of reagents used in this reaction, and the system is relatively complicated. In particular, the water removal system trifluoroacetic acid/triethyl orthoformate is used.
发明内容Contents of the invention
本发明的目的在于提供一种合成4-(2-氧代哌啶-1-基)芳基羧酸乙酯类化合物的新方法。本发明是在强碱氢化钠条件下氮负离子进攻氯取代的碳原子,发生内酰胺化关环得到产物。The object of the present invention is to provide a new method for synthesizing 4-(2-oxopiperidin-1-yl) aryl carboxylate ethyl esters. In the invention, under the condition of strong alkali sodium hydride, nitrogen negative ions attack the carbon atom substituted by chlorine, and lactamization and ring closure occur to obtain the product.
本发明所述的合成4-(2-氧代哌啶-1-基)芳基羧酸乙酯类化合物的方法,是以4-(5-氯戊酰胺基)芳基羧酸乙酯类化合物(式A)为反应原料,四氢呋喃和二氯甲烷作混合溶剂,在强碱氢化钠作用下发生内酰胺化反应得到产物4-(2-氧代哌啶-1-基)芳基羧酸乙酯类化合物(式B)。反应式如下:The method for synthesizing 4-(2-oxopiperidin-1-yl) aryl carboxylate ethyl esters described in the present invention is based on 4-(5-chloropenteramido) aryl carboxylate ethyl esters The compound (formula A) is the reaction raw material, tetrahydrofuran and dichloromethane are used as the mixed solvent, and the lactamization reaction occurs under the action of strong alkali sodium hydride to obtain the product 4-(2-oxopiperidin-1-yl)aryl carboxylic acid Ethyl esters (Formula B). The reaction formula is as follows:
Ar的结构可以为苯环、单取代苯环、多取代苯环;Het的结构可以为多种杂环,例如:吡咯环、吡啶环、哌啶环等。The structure of Ar can be benzene ring, single-substituted benzene ring, multi-substituted benzene ring; the structure of Het can be various heterocycles, for example: pyrrole ring, pyridine ring, piperidine ring, etc.
在本发明的方法中,因反应原料中包含酯基,在有水条件下极易水解,所以反应要求严格控水,避免过多的水解带来收率损失。反应使用的氢化钠既作为碱又作为除水剂。氢化钠要在氮气或氩气保护下,石油醚洗4-6次,然后油泵抽干备用。In the method of the present invention, because the reaction raw materials contain ester groups, they are easily hydrolyzed in the presence of water, so the reaction requires strict water control to avoid yield loss caused by excessive hydrolysis. The sodium hydride used in the reaction is used both as an alkali and as a water removal agent. Sodium hydride should be washed 4-6 times with petroleum ether under the protection of nitrogen or argon, and then pumped dry for later use.
本发明中,所选的溶剂是四氢呋喃和二氯甲烷的混合溶剂,对溶剂的水分要求控制在0.1%以下。In the present invention, the selected solvent is a mixed solvent of tetrahydrofuran and dichloromethane, and the moisture content of the solvent is required to be controlled below 0.1%.
本发明方法中,最好在氮气保护下加料。In the method of the present invention, it is preferable to feed under nitrogen protection.
由于产物浓缩后呈泡沫状,较难用减压浓缩的方法得到固体产物,所以该步反应选择加溶剂打浆,然后过滤得到较好的固体。Since the product is foamy after concentration, it is difficult to obtain a solid product by concentrating under reduced pressure, so this step reaction is selected to add a solvent to make a slurry, and then filter to obtain a better solid.
一个具体的步骤是:N2保护下将洗好的NaH溶解于THF中,低温下滴加溶有起始原料的DCM,滴加完毕,升温搅拌,TLC监控反应,直至起始原料归一化面积小于1.0%,加入冷水淬灭反应,萃取,打浆,过滤,洗涤,烘干。A specific step is: Dissolve the washed NaH in THF under the protection of N 2 , add dropwise DCM with the starting material at low temperature, after the addition is completed, heat up and stir, and monitor the reaction by TLC until the starting material is normalized If the area is less than 1.0%, add cold water to quench the reaction, extract, beat, filter, wash and dry.
DCM(v/w)用量相当于起始原料的8-12倍量,THF(v/w)用量相当于起始原料的5-9倍量,NaH所用摩尔量为反应原料摩尔量的3-4倍量,滴加温度为20℃以下,反应温度为20-30℃,猝灭反应的冷水(w/v)用量相当于起始原料的9-15倍量条件下,产物的纯度和收率都很高。The amount of DCM (v/w) is equivalent to 8-12 times the amount of the starting material, the amount of THF (v/w) is equivalent to 5-9 times the amount of the starting material, and the molar amount used by NaH is 3-3 times the molar amount of the reaction raw material. 4 times the amount, the dropping temperature is below 20°C, the reaction temperature is 20-30°C, and the amount of cold water (w/v) for quenching the reaction is equivalent to 9-15 times the amount of the starting material, the purity and yield of the product Rates are high.
本发明的方法与现有技术相比,具有经济、操作简单,且纯度高,产率高的优点。Compared with the prior art, the method of the invention has the advantages of economy, simple operation, high purity and high yield.
具体实施方式detailed description
在实施本发明时,氮气保护下加料。在反应过程中,多种因素会影响进程,从而改变结果。所以,要对各因素进行探究,找到一个最佳条件水平。When implementing the present invention, feed under nitrogen protection. During a reaction, a variety of factors can affect the progress and thereby alter the outcome. Therefore, it is necessary to explore various factors to find an optimal condition level.
本发明中所使用的反应原料中包含酯基,在有水条件下极易水解,所以反应要求严格控水,避免过多的水解带来收率损失。而反应中氢化钠既作为碱又作为除水剂,所以在探索最佳条件水平时氢化钠量的控制是尤为重要的。The reaction raw materials used in the present invention contain ester groups, which are easily hydrolyzed in the presence of water, so the reaction requires strict water control to avoid yield loss caused by excessive hydrolysis. In the reaction, sodium hydride is used as both alkali and water-removing agent, so the control of the amount of sodium hydride is particularly important when exploring the optimal condition level.
溶剂的用量对反应结果也有很大的影响。为使反应原料全部溶解,便于内酰胺化反应进行完全,需要对溶剂的用量进行探究。The amount of solvent also has a great influence on the reaction result. In order to dissolve all the reaction raw materials and facilitate the complete lactamization reaction, it is necessary to explore the amount of solvent used.
此外,反应时间也是一个重要的因素;以及反应温度的控制,既要反应时间内原料反应完全,又要防止由于温度偏高发生水解产生水解杂质。In addition, the reaction time is also an important factor; as well as the control of the reaction temperature, it is necessary to complete the reaction of the raw materials within the reaction time, and to prevent the generation of hydrolyzed impurities due to hydrolysis due to high temperature.
实施例1Example 1
称取0.53g起始原料1-(4-甲氧基苯基)-7-氧代-6-[4-(5-氯戊酰胺基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4,c]吡啶-3-羧酸乙酯于单口烧瓶中,加入5.3ml DCM(v/w=10),搅拌溶清,另取一干燥的三口烧瓶,N2保护,称入NaH 0.048g(2eq),加入5.3ml THF(v/w=10),20℃以下搅拌溶解。滴加起始原料的二氯甲烷溶液,温度控制在20℃以下,滴加完毕,升温至30℃搅拌24h,TLC监控反应。加入5ml冷水淬灭反应,萃取,打浆,过滤,洗涤,烘干得白色粉末产物1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代哌啶-1-基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-3-羧酸乙酯,收率为80%,纯度为55%。Weigh 0.53g starting material 1-(4-methoxyphenyl)-7-oxo-6-[4-(5-chloropenterylamino)phenyl]-4,5,6,7-tetra Hydrogen-1H-pyrazolo[3,4,c]pyridine-3-carboxylic acid ethyl ester in a one-necked flask, add 5.3ml DCM (v/w=10), stir to dissolve, and take another dry three-necked flask , N 2 protection, weighed in 0.048g (2eq) of NaH, added 5.3ml THF (v/w=10), stirred and dissolved below 20°C. The dichloromethane solution of the starting material was added dropwise, and the temperature was controlled below 20°C. After the dropwise addition was completed, the temperature was raised to 30°C and stirred for 24 hours, and the reaction was monitored by TLC. Add 5ml of cold water to quench the reaction, extract, beat, filter, wash, and dry to obtain the white powder product 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidine -1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester, yield 80%, purity 55 %.
实施例2Example 2
与实施例1的区别在于:加入NaH 0.072g(3eq),其他操作基本相同的情况下,得到白色粉末产物的收率为95%,纯度为81%。The difference from Example 1 is: adding NaH 0.072g (3eq), and other operations are basically the same, the yield of the white powder product is 95%, and the purity is 81%.
实施例3Example 3
与实施例1的区别在于:加入NaH 0.1g(4eq),其他操作基本相同的情况下,得到白色粉末产物的收率为94%,纯度为80%。The difference with Example 1 is: adding NaH 0.1g (4eq), and other operations are basically the same, the yield of the white powder product is 94%, and the purity is 80%.
实施例4Example 4
与实施例1的区别在于:加入NaH 0.084g(3.5eq),其他操作基本相同的情况下,得到白色粉末产物的收率为95.2%,纯度为86.3%。The difference from Example 1 is that: 0.084g (3.5eq) of NaH was added, and other operations were basically the same, the yield of the white powder product was 95.2%, and the purity was 86.3%.
实施例5Example 5
称取1.05g起始原料1-(4-甲氧基苯基)-7-氧代-6-[4-(5-氯戊酰胺基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4,c]吡啶-3-羧酸乙酯于单口烧瓶中,加入8ml DCM(v/w=8),搅拌溶清,另取一干燥的三口烧瓶,N2保护,称入NaH 0.17g(3.5eq),加入5ml THF(v/w=5),20℃以下搅拌溶解。滴加起始原料的二氯甲烷溶液,温度控制在20℃以下,滴加完毕,升温至30℃搅拌24h,TLC监控反应。加入10ml冷水淬灭反应,萃取,打浆,过滤,洗涤,烘干得白色粉末产物1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代哌啶-1-基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-3-羧酸乙酯,收率为92%,纯度为85.7%。Weigh 1.05 g of starting material 1-(4-methoxyphenyl)-7-oxo-6-[4-(5-chloropentanylamino)phenyl]-4,5,6,7-tetra Hydrogen-1H-pyrazolo[3,4,c]pyridine-3-carboxylic acid ethyl ester in a one-necked flask, add 8ml DCM (v/w=8), stir to dissolve, and take another dry three-necked flask, N 2 protected, weighed in 0.17g (3.5eq) of NaH, added 5ml of THF (v/w=5), stirred and dissolved below 20°C. The dichloromethane solution of the starting material was added dropwise, and the temperature was controlled below 20°C. After the dropwise addition was completed, the temperature was raised to 30°C and stirred for 24 hours, and the reaction was monitored by TLC. Add 10ml of cold water to quench the reaction, extract, beat, filter, wash, and dry to obtain the white powder product 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidine -1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester, yield 92%, purity 85.7 %.
实施例6Example 6
与实施例5的区别在于:加入8ml DCM(v/w=12),加入5ml THF(v/w=9),其他操作基本相同的情况下,得到白色粉末产物的收率为95%,纯度为86.1%。The difference with Example 5 is: add 8ml DCM (v/w=12), add 5ml THF (v/w=9), under the situation that other operations are basically the same, the yield that obtains white powder product is 95%, purity was 86.1%.
实施例7Example 7
称取2.1g起始原料1-(4-甲氧基苯基)-7-氧代-6-[4-(5-氯戊酰胺基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4,c]吡啶-3-羧酸乙酯于单口烧瓶中,加入25.2ml DCM(v/w=12),搅拌溶清,另取一干燥的三口烧瓶,N2保护,称入NaH 0.34g(3.5eq),加入19ml THF(v/w=9),20℃以下搅拌溶解。滴加起始原料的二氯甲烷溶液,温度控制在20℃以下,滴加完毕,升温至30℃搅拌,TLC监控反应。加入20ml冷水淬灭反应,萃取,打浆,过滤,洗涤,烘干得白色粉末产物1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代哌啶-1-基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-3-羧酸乙酯,收率为94%,纯度为84%。Weigh 2.1 g of starting material 1-(4-methoxyphenyl)-7-oxo-6-[4-(5-chlorovalerylamino)phenyl]-4,5,6,7-tetra Hydrogen-1H-pyrazolo[3,4,c]pyridine-3-carboxylic acid ethyl ester in a one-necked flask, add 25.2ml DCM (v/w=12), stir to dissolve, and take another dry three-necked flask , under N 2 protection, weighed in 0.34g (3.5eq) of NaH, added 19ml of THF (v/w=9), stirred and dissolved below 20°C. The dichloromethane solution of the starting material was added dropwise, and the temperature was controlled below 20°C. After the dropwise addition was completed, the temperature was raised to 30°C and stirred, and the reaction was monitored by TLC. Add 20ml of cold water to quench the reaction, extract, beat, filter, wash, and dry to obtain the white powder product 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidine -1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester, yield 94%, purity 84 %.
实施例8Example 8
与实施例7的区别在于:滴加完毕后,在15℃搅拌反应,其他操作基本相同的情况下,TLC监控反应,起始原料归一化面积小于1.0%时,反应时间延长到36h,得到白色粉末产物的收率为93%,纯度为80.3%。The difference with Example 7 is that: after the dropwise addition, the reaction was stirred at 15°C, and the other operations were basically the same, and the reaction was monitored by TLC. When the normalized area of the starting material was less than 1.0%, the reaction time was extended to 36h, and the obtained The yield of the white powder product was 93%, and the purity was 80.3%.
实施例9Example 9
与实施例7的区别在于:滴加完毕后,在25℃搅拌反应,其他操作基本相同的情况下,TLC监控反应,起始原料归一化面积小于1.0%时,反应时间为22h,得到白色粉末产物的收率为95.2%,纯度为88.6%。The difference with Example 7 is that: after the dropwise addition, the reaction was stirred at 25°C, and the other operations were basically the same, and the reaction was monitored by TLC. When the normalized area of the starting material was less than 1.0%, the reaction time was 22h, and a white The yield of the powder product was 95.2%, and the purity was 88.6%.
实施例10Example 10
称取2.1g起始原料1-(4-甲氧基苯基)-7-氧代-6-[4-(5-氯戊酰胺基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4,c]吡啶-3-羧酸乙酯于单口烧瓶中,加入25.2ml DCM(v/w=12),搅拌溶清,另取一干燥的三口烧瓶,N2保护,称入NaH 0.34g(3.5eq),加入19ml THF(v/w=9),20℃以下搅拌溶解。滴加起始原料的二氯甲烷溶液,温度控制在20℃以下,滴加完毕,升温至25℃搅拌,对不同时间采取取样跟踪,反应时间分别设置为12h、20h、22h、24h、30h,反应液采用HPLC监控,随着反应的进行,在不同时间显示起始物料反应程度不同,12h时原料剩余30.83%,主峰归一化面积67.95%,22h时原料归一化面积小于1.0%,主峰归一化面积97.8%,30h时主峰归一化面积80.46%,产生较大未知杂质且水解杂质变大。Weigh 2.1 g of starting material 1-(4-methoxyphenyl)-7-oxo-6-[4-(5-chlorovalerylamino)phenyl]-4,5,6,7-tetra Hydrogen-1H-pyrazolo[3,4,c]pyridine-3-carboxylic acid ethyl ester in a one-necked flask, add 25.2ml DCM (v/w=12), stir to dissolve, and take another dry three-necked flask , under N 2 protection, weighed in 0.34g (3.5eq) of NaH, added 19ml of THF (v/w=9), stirred and dissolved below 20°C. Add the dichloromethane solution of the starting material dropwise. The temperature is controlled below 20°C. After the dropwise addition is completed, the temperature is raised to 25°C and stirred. Sampling and tracking are taken at different times. The reaction time is set to 12h, 20h, 22h, 24h, and 30h respectively. The reaction solution was monitored by HPLC. As the reaction progressed, the reaction degree of the starting materials was different at different times. At 12 hours, the remaining raw materials were 30.83%, and the normalized area of the main peak was 67.95%. At 22 hours, the normalized area of the raw materials was less than 1.0%, and the main peak The normalized area was 97.8%, and the normalized area of the main peak was 80.46% at 30 h, resulting in larger unknown impurities and larger hydrolyzed impurities.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610073279.5A CN105732618A (en) | 2016-02-02 | 2016-02-02 | Method for synthesizing 4-(2-oxo-piperidine-1-yl)aryl-carboxylic ethyl ester compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610073279.5A CN105732618A (en) | 2016-02-02 | 2016-02-02 | Method for synthesizing 4-(2-oxo-piperidine-1-yl)aryl-carboxylic ethyl ester compound |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105732618A true CN105732618A (en) | 2016-07-06 |
Family
ID=56242237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610073279.5A Pending CN105732618A (en) | 2016-02-02 | 2016-02-02 | Method for synthesizing 4-(2-oxo-piperidine-1-yl)aryl-carboxylic ethyl ester compound |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105732618A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050245566A1 (en) * | 2001-12-10 | 2005-11-03 | Jiacheng Zhou | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones |
CN101967145A (en) * | 2010-09-09 | 2011-02-09 | 华东理工大学 | Method for preparing antithrombotic medicament apixaban |
CN104045637A (en) * | 2014-04-18 | 2014-09-17 | 河北科技大学 | Apixaban preparation method |
CN104844593A (en) * | 2014-12-15 | 2015-08-19 | 上海同昌生物医药科技有限公司 | Synthetic method for Apixaban drug intermediate |
-
2016
- 2016-02-02 CN CN201610073279.5A patent/CN105732618A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050245566A1 (en) * | 2001-12-10 | 2005-11-03 | Jiacheng Zhou | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones |
CN101967145A (en) * | 2010-09-09 | 2011-02-09 | 华东理工大学 | Method for preparing antithrombotic medicament apixaban |
CN104045637A (en) * | 2014-04-18 | 2014-09-17 | 河北科技大学 | Apixaban preparation method |
CN104844593A (en) * | 2014-12-15 | 2015-08-19 | 上海同昌生物医药科技有限公司 | Synthetic method for Apixaban drug intermediate |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102766138B (en) | A kind of preparation method of Azilsartan | |
CN104974073B (en) | A kind of method for preparing Silodosin intermediate | |
CN104470898A (en) | Cycloalkyl Acid Derivative, Preparation Method Thereof, And Pharmaceutical Application Thereof | |
CN105085544B (en) | A kind of synthetic method of Tazobactam Sodium benzhydryl ester | |
CN105949240B (en) | 4 phosphonic acids 1,5 of ionic liquid-catalyzed synthesis replace the method for 1,2,3 triazole compounds | |
CN103562191B (en) | Nitrogenous saturated heterocyclic compound | |
CN110483476B (en) | A process for preparing benzoselenophene compounds by catalytic method | |
CN105732618A (en) | Method for synthesizing 4-(2-oxo-piperidine-1-yl)aryl-carboxylic ethyl ester compound | |
CN108707067B (en) | Preparation method of 1-aryl-4, 4, 4-trifluoro-1-butanone compound | |
CN104016877A (en) | Acetylaniline compounds and application thereof in preparation of mirabegron | |
CN105315231A (en) | Preparation method of linezolid related substance | |
CN103880776B (en) | A kind of method preparing 2-amino-5-alkyl-1,3,4-thiadiazoles | |
CN106866573A (en) | A kind of method of the ketone compounds of 1,3,4 oxadiazole 2 such as carbon dioxide synthesis oxadiazon | |
CN113698349B (en) | A kind of aqueous phase photocatalytic preparation method of 2-(2-phenyl-2H-indazol-3-yl) acetate compound | |
CN105622452A (en) | AHU-377 crystal-type free acid, preparation method and applications thereof | |
CN108794375A (en) | A kind of pabishta intermediate and its synthesis and application | |
CN110724094B (en) | Quinoline compound and synthesis method thereof | |
JP7094942B2 (en) | Method for producing benzimidazole derivative | |
CN108026017A (en) | The manufacture method of the manufacture method of acyl halide solution, mixed solution and monoester compound | |
CN104926807A (en) | Rivaroxaban related substance 'diamine' and synthesis method thereof | |
CN106632001A (en) | Preparation method of 4-(bromoacetyl) pyridine hydrobromide | |
CN105884766B (en) | A kind of method for synthesizing minot phosphoric acid intermediate | |
CN109956886A (en) | (Z)-[(4- methoxyphenyl) hydrazono-] preparation method of ethyl chloroacetate | |
CN109232531B (en) | Preparation method of cabitinib | |
CN108164480B (en) | A kind of synthetic method of diaryl furan compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160706 |
|
WD01 | Invention patent application deemed withdrawn after publication |